ENTERA BIO LTD. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ENTERA BIO LTD. (ENTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-07
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-27 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-27 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-28 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-05 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-08 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-08 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |